

INNOVUS PHARMACEUTICALS, INC.

Form 8-K

May 29, 2018

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

Form 8-K

Current Report  
Pursuant to Section 13 or 15(d)  
of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 29, 2018

INNOVUS PHARMACEUTICALS, INC.  
(Exact name of registrant as specified in its charter)

|   |                             |   |
|---|-----------------------------|---|
| NEVADA  | 000-52991                   | 90-0814124                                    |
| (State or other jurisdiction<br>of incorporation) | (Commission<br>File Number) | (I.R.S.<br>Employer<br>Identification<br>No.) |

8845  
REHCO  
ROAD, 92121  
SAN  
DIEGO,  
CA 92129  
(Address  
of  
principal (Zip Code)  
executive  
offices)

Registrant's telephone number, including area code: (858) 964-5123

Not applicable.  
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 5.07 Submission of Matters to a Vote of Security Holders.

Innovus Pharmaceuticals, Inc. (the “Company”) held its 2018 annual meeting of stockholders on May 29, 2018 (the “Annual Meeting”). The Company filed its definitive proxy statement for the proposals voted upon at the Annual Meeting with the Securities and Exchange Commission on April 30, 2018.

At the close of business on April 26, 2018, the record date of the Annual Meeting, the Company had 194,046,100 shares of common stock issued and outstanding. The holders of a total of 116,937,689 shares of common stock were present at the Annual Meeting, either in person or by proxy, which total constituted a quorum of the issued and outstanding shares on the record date of the Annual Meeting.

Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting

(a)  
To elect Director nominees named below to serve until the 2019 Annual Meeting of Stockholders. The named nominees were so elected, with the votes thereon at the Annual Meeting as follows:

Final Voting Results

| Nominee          | For        | Withheld  | Broker Non-Vote |
|------------------|------------|-----------|-----------------|
| Dr. Bassam Damaj | 76,843,932 | 1,080,765 | 39,012,992      |
| Dr. Henry Esber  | 76,331,120 | 1,593,577 | 39,012,992      |
| Vivian Liu       | 76,611,032 | 1,313,665 | 39,012,992      |
| Dr. Ziad Mirza   | 76,604,932 | 1,319,765 | 39,012,992      |
| Dean Nuhaily     | 76,676,020 | 1,248,677 | 39,012,992      |

(b)  
To ratify the selection by the Audit Committee of the Company’s Board of Directors of Hall & Company, Inc as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2018. This proposal was approved, with the votes thereon at the Annual Meeting as follows:

Final Voting Results

| For         | Against | Abstain | Broker Non-Vote |
|-------------|---------|---------|-----------------|
| 116,175,557 | 554,982 | 207,150 | 0               |



SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INNOVUS PHARMACEUTICALS, INC.

By: /s/ Randy Berholtz  
Randy Berholtz  
Executive Vice President, Corporate Development and General Counsel

Date: May 29, 2018